Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas

被引:26
|
作者
Kehrer-Sawatzki, Hildegard [1 ]
Kluwe, Lan [2 ]
Friedrich, Reinhard E. [3 ]
Summerer, Anna [1 ]
Schaefer, Eleonora [1 ]
Wahllaender, Ute [4 ]
Matthies, Cordula [5 ]
Gugel, Isabel [6 ]
Farschtschi, Said [2 ]
Hagel, Christian [7 ]
Cooper, David N. [8 ]
Mautner, Victor-Felix [2 ]
机构
[1] Univ Ulm, Inst Human Genet, D-89081 Ulm, Germany
[2] Univ Hosp Hamburg Eppendorf, Dept Neurol, D-20246 Hamburg, Germany
[3] Univ Hosp Hamburg Eppendorf, Dept Oral & Maxillofacial Surg, D-20246 Hamburg, Germany
[4] KBO Children Clin Ctr Munich, D-81377 Munich, Germany
[5] Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany
[6] Univ Hosp Tubingen, Dept Neurosurg, D-72076 Tubingen, Germany
[7] Univ Hosp Hamburg Eppendorf, Dept Neuropathol, D-20246 Hamburg, Germany
[8] Cardiff Univ, Inst Med Genet, Sch Med, Cardiff CF14 4XN, S Glam, Wales
关键词
TUMOR-SUPPRESSOR GENE; UNILATERAL VESTIBULAR SCHWANNOMA; NEUROFIBROMATOSIS; PATIENTS; GERM-LINE MUTATIONS; FAMILIAL SCHWANNOMATOSIS; TYPE-2; SOMATIC MOSAICISM; SPORADIC SCHWANNOMATOSIS; DIAGNOSTIC-CRITERIA; LZTR1; MUTATION;
D O I
10.1007/s00439-018-1909-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Schwannomatosis and neurofibromatosis type 2 (NF2) are both characterized by the development of multiple schwannomas but represent different genetic entities. Whereas NF2 is caused by mutations of the NF2 gene, schwannomatosis is associated with germline mutations of SMARCB1 or LZTR1. Here, we studied 15 sporadic patients with multiple non-intradermal schwannomas, but lacking vestibular schwannomas and ophthalmological abnormalities, who fulfilled the clinical diagnostic criteria for schwannomatosis. None of them harboured germline NF2 or SMARCB1 mutations as determined by the analysis of blood samples but seven had germline LZTR1 variants predicted to be pathogenic. At least two independent schwannomas from each patient were subjected to NF2 mutation testing. In five of the 15 patients, identical somatic NF2 mutations were identified (33%). If only those patients without germline LZTR1 variants are considered (n = 8), three of them (37.5%) had mosaic NF2 as concluded from identical NF2 mutations identified in independent schwannomas from the same patient. These findings imply that a sizeable proportion of patients who fulfil the diagnostic criteria for schwannomatosis, are actually examples of mosaic NF2. Hence, the molecular characterization of tumours in patients with a clinical diagnosis of schwannomatosis is very important. Remarkably, two of the patients with germline LZTR1 variants also had identical NF2 mutations in independent schwannomas from each patient which renders differential diagnosis of LZTR1-associated schwannomatosis versus mosaic NF2 in these patients very difficult.
引用
收藏
页码:543 / 552
页数:10
相关论文
共 3 条
  • [1] Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas
    Hildegard Kehrer-Sawatzki
    Lan Kluwe
    Reinhard E. Friedrich
    Anna Summerer
    Eleonora Schäfer
    Ute Wahlländer
    Cordula Matthies
    Isabel Gugel
    Said Farschtschi
    Christian Hagel
    David N. Cooper
    Victor-Felix Mautner
    Human Genetics, 2018, 137 : 543 - 552
  • [2] Schwannomatosis associated schwannomas show a different NF2 mutational spectrum compared to Neurofibromatosis type 2 patients
    Paganini, I.
    Capone, G. L.
    Putignano, A.
    Sestini, R.
    Gensini, F.
    Porfirio, B.
    Marozza, A.
    Papi, L.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 450 - 450
  • [3] THE MAYO CLINIC MULTIDISCIPLINARY NF2 CLINIC EXPERIENCE OF BEVACIZUMAB IN NEUROFIBROMATOSIS TYPE 2-RELATED SCHWANNOMATOSIS PATIENTS WITH VESTIBULAR SCHWANNOMAS
    Webb, M. J.
    Webb, L. M.
    Van Gompel, J. J.
    Link, M. J.
    Neff, B. A.
    Carlson, M. L.
    Driscoll, C. W.
    Ruff, M. W.
    Anderson, K. A.
    Neth, B. J.
    Kizilbash, S. H.
    Uhm, J. H.
    Lane, J. I.
    Benson, J. C.
    Blezek, D. J.
    Mehta, P. M.
    Bathla, G.
    Sener, U. T.
    NEURO-ONCOLOGY, 2023, 25